Cell Culture Industry

The global cell culture market was valued at approximately USD 16.59 billion in 2022 and is projected to experience a compound annual growth rate (CAGR) of 11.32% from 2023 to 2030. This growth is largely driven by the increasing adoption of cell culture methods aimed at developing substrates that ensure the safe production of viral vaccines, alongside a rising global demand for advanced therapy medicinal products. Additionally, the emergence of innovative three-dimensional cell culture techniques, along with a growing necessity for these technologies in biopharmaceutical development and vaccine production, is anticipated to further propel market expansion throughout the forecast period.

The COVID-19 pandemic has created significant opportunities for researchers to explore the new virus, leading to the development of therapeutic and diagnostic tools. Many leading pharmaceutical and biotechnology firms have ramped up their research and development activities to create groundbreaking vaccines, therapies, and testing kits. This surge in R&D efforts has resulted in a notable increase in the demand for cell culture tools within research applications.

Moreover, the pandemic has intensified the need for novel cell-based models, organoids, and high-throughput screening platforms to support research and drug discovery initiatives. The urgent need to address the pandemic has also led to a heightened demand for bioreactors and culture systems specifically for vaccine production and drug testing applications. In response to this increased demand, numerous emerging and established companies have undertaken various initiatives to capitalize on the burgeoning need for cell culture products stemming from the challenges posed by the COVID-19 pandemic.

Gather more insights about the market drivers, restrains and growth of the Cell Culture Market

Application Insights

• The biopharmaceutical production application segment dominated the market in 2022, accounting for a substantial revenue share of 15%. This significant market presence is largely due to the increasing utilization of advanced cell culture techniques, particularly involving mammalian cell lines such as Chinese hamster ovary (CHO) cells. These cell lines are pivotal in the production of a wide range of biopharmaceuticals, including monoclonal antibodies and therapeutic proteins, which are essential for treating various diseases. The rising demand for alternative medicines, driven by a growing preference for biologics over traditional pharmaceuticals, has further fueled this segment's expansion.
• Recent innovations in grafting procedures and the emergence of new alternatives in personalized therapy have broadened the potential applications within the biopharmaceutical sector. Personalized therapies, which tailor treatment plans based on individual genetic profiles and disease characteristics, are becoming increasingly popular. This shift towards personalized medicine underscores the need for advanced cell culture systems that can support the development and production of customized therapeutic solutions, thus enhancing patient outcomes and satisfaction.
• In parallel, the diagnostics segment is expected to experience remarkable growth, projected to achieve a compound annual growth rate (CAGR) of 29% from 2023 to 2030. The use of cell cultures in metabolomics is instrumental in identifying biomarkers linked to various pathologically relevant conditions, allowing for earlier detection and more accurate disease characterization. These biomarkers can provide critical insights into the underlying mechanisms of diseases, facilitating the development of targeted diagnostic tests.
• Additionally, metabolites derived from cell cultures play a crucial role in the diagnosis of cancer and its recurrence. The ability to analyze these metabolites enhances the understanding of tumor biology and progression, leading to improved diagnostic accuracy. This growing recognition of the importance of cell culture media products in disease diagnosis is expected to drive significant demand in the diagnostics sector, as healthcare providers increasingly rely on these advanced techniques to monitor patient health and tailor treatment strategies effectively.
• Overall, the interplay between advancements in biopharmaceutical production and diagnostics, alongside the increasing demand for personalized and alternative therapies, positions both segments for robust growth in the coming years. This dynamic landscape highlights the critical role that innovative cell culture techniques will play in shaping the future of healthcare and therapeutic development.

Order a free sample PDF of the Cell Culture Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com/

Follow Us: LinkedIn | Twitter